was conducted. Pre CRT tumour staging, treatment-related hematologic toxicities and pathologic nodal response data were recorded. Univariable and Multivariable analyses were performed using Bayesian logistic regression models. Results: Two hundred and six patients with clinically node positive RC were included in this study. The mean number of excised nodes was 16.35. One hundred and seventeen patients (56.8%) achieved a pathologic complete nodal response. Higher pre-treatment carcinoembryonic antigen (CEA) level (p = 0.0072) and presence of lymphovascular space invasion (LVI) in the surgical specimen (p = 0.0002) were independent predictors of lack of nodal response. In the univariable analysis, there was a tendency to a better response in patients who developed less treatment-induced lymphocytopenia. Conclusions: Pre-treatment CEA and presence of LVI predicted less pathological nodal response post CRT for rectal cancer. LVI is a pathological finding, however, signs of vascular invasion can be detected on the pre-treatment MRI. These results could potentially be used to identify favourable responders to CRT and guide management strategies of rectal cancer especially when organ and function preservation are pursued.
Purpose: Stereotactic body radiotherapy (SBRT) can treat hepatocellular (HCC) patients who are not eligible for surgery, trans-arterial chemoembolization or radiofrequency ablation. This study aims to compare the efficacy and toxicity of SBRT to small tumours (< 4.4 cm, our median population size) and moderate to large tumours (≥ 4.4 cm).
Methods and Materials:
A retrospective study of the first 48 provincially treated HCC patients (March 2011-July 2015) was conducted. All patients were discussed at multidisciplinary rounds and considered ineligible for further standard local therapies. Local control (LC), progression free survival (PFS), overall survival (OS) and toxicities were analyzed. Results: Fifty-one separate hepatomas were treated with a median size of 4.4cm (range: 1.3-15.6cm). Baseline demographics, performance status, previous liver-directed treatments, and Child's Pugh (CP) score were similar between the groups. Hepatitis B was more common in the ≥4.4cm group while Hepatitis C was more common in the < 4.4 cm group (p = 0.05). RT doses were 36 to 50 Gy in three to 10 fractions, with 87% of patients receiving 45 Gy in 3 or 5 fractions. Twenty-eight (55%) hepatomas were treated with a biological equivalent dose (BED10) ≥ 100 Gy and 45 (88.3%) were treated with a BED10 ≥ 80 Gy. Tumours <4.4cm were more likely to be treated with a BED10 ≥ 80 Gy (p < 0.001). Seven patients (15%) had worsened CP score by > 1 point at three months post-SBRT, but this was not different between the two groups (p = 0.86). LC for all patients was 94% at one and two years, and was comparable for tumours < 4.4 cm and ≥ 4.4 cm (two year LC: 96% for < 4.4 cm versus 92% for ≥ 4.4 cm, p = 0.91). OS for all patients was 65% at two years (87% for < 4.4 cm versus 46% for ≥ 4.4 cm, p = 0.07). PFS was 38% at two years for all patients, and did not differ significantly between groups (p = 0.70). On univariate analysis, BED10 ≥ 80 Gy was the only factor associated with improved PFS, while both BED10 ≥ 80 Gy and normal baseline AFP were associated with improved OS. Conclusions: SBRT provides high local control for patients with inoperable HCC and can be delivered with acceptable risk for post-treatment hepatic injury even for moderate to large sized tumours. Radiation doses above BED10 of 80 Gy improved PFS and OS in our cohort.
